If you buy CBD products in Europe, there's a number you need to know: 2 milligrams per day. That's the provisional safe daily intake limit set by the European Food Safety Authority (EFSA) for cannabidiol — and it's reshaping the entire EU CBD cannabis market statistics in 2026.
+ + + ++ + + + + + + +To put that figure in perspective: most CBD oil drops, capsules, and gummies on European shelves are dosed far higher. A standard 5% CBD oil delivers around 5 mg per drop. A single CBD gummy typically contains 10–25 mg. A typical daily serving recommended on most products ranges from 10 to 80 mg. Against EFSA's 2 mg limit, virtually every mainstream CBD supplement now sits in legally ambiguous or outright non-compliant territory.
+ + + + + + + + + + + +Where the 2mg Figure Comes From
+ + + + + + + + + + + +EFSA arrived at its provisional acceptable daily intake (ADI) through a systematic review of available toxicological data. The authority assessed studies on CBD's effects on the liver, the endocrine system, and the developing nervous system. After applying standard safety factors and adjusting for body weight, EFSA settled on 0.0275 mg per kilogram of body weight per day as the safe threshold — which translates to approximately 1.9–2.1 mg/day for an average European adult of 70 kg.
+ + + + + + + + + + + +The word "provisional" is important here. EFSA acknowledges that the evidence base is incomplete. Many existing studies used pharmaceutical-grade CBD (like Epidiolex) at clinical doses, not the lower-dose supplement products CBD oil guide for consumers actually use. The authority has called for better dose-response studies before a definitive ADI can be established. But "provisional" doesn't mean "non-binding" — EU regulators and national agencies are treating this limit as the operative safety standard now.
+ ++ + + + + + + + + +What This Means for CBD Products on the EU Market
+ + + + + + + + + + + +The practical implications are sweeping. Under the EU's EU CBD novel food rejection Regulation, CBD-containing food supplements require pre-market authorization before they can legally be sold. No CBD food supplement has yet received that authorization — a situation that has persisted for years while regulators waited for safety data. EFSA's 2 mg/day limit now sets a dramatically low ceiling for any future authorizations.
++ + + + + + + + + + +
For manufacturers, this creates a nearly impossible commercial position. A 2 mg/day limit means a product can only contain 2 mg of CBD per serving — and must also guarantee that consumers don't double up (taking multiple servings or using multiple products). The economics of selling a 2 mg CBD product at competitive prices are brutally challenging given current extraction and production costs.
+ + + + + + + + + + + +For retailers, the risk calculus has shifted. Products that were previously sold in a regulatory gray zone — unenforced but technically unauthorized — are now clearly on the wrong side of a published safety limit. The legal exposure is real.
+ + + + + + + + + + + +
Germany's evolving cannabis regulations Zero Tolerance Enforcement
+ + ++ + + + + + + + +Nowhere is the enforcement pressure more acute than Germany. The Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL — Germany's Federal Office of Consumer Protection and Food Safety) has maintained a zero-tolerance posture toward unauthorized CBD food supplements throughout 2025 and into 2026.
+ + + + + + + + + + + +German food authorities have been conducting systematic market sweeps, removing products from physical and online shelves, and issuing administrative fines. Retailers selling CBD supplements — including oils, capsules, and edibles — face enforcement action regardless of the CBD concentration involved. The operative logic is simple: if the product hasn't received Novel Food authorization, it's not legal to sell as a food supplement. EFSA's limit provides additional regulatory ammunition, but German enforcement was already aggressive before it.
+ + + + + + + + + + + +For German consumers, this means the CBD products they've been buying — often from health food stores (Reformhäuser), pharmacies (Apotheken), or online retailers — have increasingly disappeared from shelves or been relabeled and repositioned as "aroma products" or cosmetics in attempts to sidestep food regulation.
+ + + + + + + + + + + +The 2026 Authorization Process: Stricter Than Ever
+ + + + + + + + + + + +Despite the hostile regulatory environment, some manufacturers are still pursuing Novel Food authorization. But the path has gotten harder. EFSA's updated 2026 submission requirements demand more robust evidence than previous application cycles required:
+ + + + + + + + + + + +- + + + + + +
- Peer-reviewed dose-response studies at consumer-relevant doses (not just clinical doses) + + + + + +
- Long-term safety data on repeat exposure + + + + + +
- Special population data — pregnant women, children, and adolescents are explicitly excluded from standard data extrapolation and require dedicated studies + + + + + +
- Pharmacokinetic data showing absorption and metabolism at low doses + + + + + +
Generating this evidence base takes years and costs millions of euros. Only well-capitalized companies can realistically pursue authorization. The regulatory burden effectively consolidates the market around large players while locking out smaller artisanal producers.
+ + + + + + + + + + + +
UK and US cannabis regulatory approach: A Tale of Regulatory Divergence
+ + + + + + + + + + + +The contrast with non-EU markets couldn't be starker. In the United Kingdom, the Food Standards Agency (FSA) has taken a more permissive — and arguably more pragmatic — approach. The FSA recommends that healthy adults limit CBD intake to 10 mg per day as a precautionary measure, while acknowledging that many products exceed this level. Unlike the EU, the UK has not imposed a hard authorization requirement that makes the entire market technically illegal.
+ + + + + + + + + + + +In the United States, the regulatory picture is different again. The FDA has not approved CBD as a dietary supplement and technically treats it as a drug ingredient (due to Epidiolex's approval), but enforcement is inconsistent. The other minor cannabinoids-derived CBD market operates largely under state regulation, with most states permitting sales up to 25–50 mg per serving without requiring pre-market approval. Some states have implemented their own testing and labeling requirements, but nothing approaching the EU's Novel Food authorization gatekeeping.
+ + + + ++ + + + + + +This transatlantic divergence creates a significant problem for international brands. A product legally manufactured and sold in the US or UK cannot simply be shipped to EU consumers without running afoul of Novel Food rules. The 2 mg EFSA limit makes cross-border e-commerce of CBD supplements virtually impossible within the EU framework.
+ + + + + + + + + + + +What Consumers Should Know Right Now
+ + + + + + + + + + + +If you're a consumer in the EU currently using CBD products, here's a practical breakdown of where things stand:
+ + + + + + + + + + + +- + + + + + +
- Your products are technically unauthorized. No CBD food supplement has received Novel Food approval, regardless of brand reputation or product quality. + + + + + +
- EFSA's 2 mg limit is a safety guideline, not a dose proven to be harmful above. The limit is derived from animal studies and applies a precautionary safety factor. It doesn't mean that 10 mg of CBD daily will harm you — it means EFSA cannot currently confirm long-term safety above this threshold. + + + + + +
- Enforcement varies by country. Germany is the strictest enforcer. Other EU member states are more lenient in practice, even if the legal framework is identical. + + + + + +
- CBD cosmetics and CBD flower (for aromatherapy use) exist in a different regulatory category and are not subject to Novel Food rules. Topical CBD creams and balms are unaffected by the EFSA food supplement limit. + + + + + +
- Watch for product reformulations. Some manufacturers are reducing CBD content per serving to approach the 2 mg threshold while maintaining products on the market. + + + + + +
The Bigger Picture: Europe's CBD Policy Crossroads
+ + + + + + + + + + + +Europe is at a regulatory crossroads on CBD. The evidence strongly suggests that low-dose CBD supplements are safe for healthy adults — but EFSA has set a bar so low that practically no supplement product can meet it. The result is a paradox: a market that regulators have implicitly tolerated for years is now being squeezed by a scientific safety assessment that, while technically defensible, produces an outcome that bears little resemblance to actual consumer risk.
+ + + + + + + + + + + +Industry advocates argue that the 2 mg limit reflects over-caution — applying safety factors appropriate for novel pharmaceutical compounds to botanical extracts with a long history of human use. They point to the hemp plant's traditional uses and the extensive epidemiological data from the many millions of CBD supplement users in the UK and US without reported mass adverse events.
+ + + + + + + + + + + +EFSA's position is that it must rely on the data it has, and the data doesn't yet support a higher ADI. Both sides have a point.
+ + + + + + + + + + + +What's clear is that the status quo — a large, commercially active CBD market operating outside formal authorization — cannot persist indefinitely. Either companies generate the evidence to support higher authorized doses, or the EU doubles down on enforcement and the market contracts sharply. The 2 mg limit is the forcing function that will determine which outcome prevails.
+ + + + + + + + + + + +What to Watch in the Coming Months
+ + + + + + + + + + + +Several developments will shape where the EU CBD story goes next:
+ + + + + + + + + + + +- + + + + + +
- Novel Food application outcomes: A handful of applications are currently under review. If any succeed — even at low authorized doses — it would create a template for the industry. + + + + + +
- European Commission guidance: The Commission may issue policy guidance that addresses the enforcement gap between the legal framework and market reality. + + + + + +
- German court cases: Several legal challenges to BVL enforcement actions are working through German administrative courts. Court rulings could clarify or limit enforcement scope. + + + + + +
- EFSA data review timeline: EFSA has indicated it will revisit the ADI once better dose-response data is available. New studies are underway that could support revision within 2–3 years. + + + + + +
For now, EU consumers who use CBD supplements are navigating a market in genuine legal and regulatory uncertainty. The 2 mg limit isn't the final word — but it is the loudest word regulators have spoken yet on CBD safety in Europe.
+ + + + + + + + + + + +Sources: EFSA Scientific Opinion on CBD (2025), German BVL enforcement announcements, UK FSA CBD guidance, US FDA CBD policy statements.
Written by
The Green Treasure Editorial Team
Independent cannabis journalism backed by science. We cover terpenes, vaporizers, edibles, growing and health.
Stay in the green loop
Expert guides, terpene science, growing tips, and gear reviews — delivered to your inbox. No spam, ever.
No spam. Unsubscribe anytime.
